CEVEC Pharmaceuticals GmbH

CEVEC is a biotechnology company specialized in the production of biopharmaceuticals using its proprietary CAP-Technology, a unique human suspension cell-based production platform.

CAP-GT cell lines enable scalable viral gene therapy vector production with easy handling and competitive production costs when compared to adherent cell culture systems. In addition, the Company has developed a helper-free AAV (adeno-associated virus) packaging cell line for scalable stable gene therapy vector production independent of transient transfection or helper virus.

CAP-Go enables the production of recombinant proteins previously out of reach that are notoriously difficult to express in conventional cell lines including blood coagulation factors, C1-Inhibitor and others.


Field of Activity
Development and licensing of cell-based production platforms for biopharmaceuticals
Ownership Structure and Financing Privately owned; investors are Peppermint VenturePartners, Creathor Venture, NRW.Bank, KfW Bank, G.A.T. Holding, Investtodate GmbH and several private persons.
Partners Selected license partners: Beckman Research Institute, BioLamina AB, Biotest AG, CellGenix GmbH, CSL Limited, Généthon, medac, PlasmidFactory GmbH & Co. KG and Provecs Medical GmbH CDMO partners: Paragon Bioservices Inc. and GenIbet Biopharmaceuticals
Technology and Unique Selling Point CEVEC´s human suspension cell-based CAP technology provides fully scalable, clinical-grade good manufacturing practice (GMP) compatible solutions for the production of viral gene therapy vectors and recombinant glycoproteins. The CAP-GT platform includes a helperfree AAV packaging cell line for stable vector production and RCA-free production of adenoviral vectors for gene therapy applications. The CAP-Go system provides outstanding pharmacokinetic profi les and characteristics in terms of authentic and tailor-made glycosylation capabilities as well as high yield production of complex proteins.
Products / Services Cell line and process development and technology licensing for the pro duction of tailor-made recombinant glycoproteins and gene therapy vectors.
Membership in networks / associations BioRiver, Bio Cologne, Bio Deutschland, BIOCOM, Dechema, VCI
Date of Incorporation / Number of Employees 2003 / 30 employees


Telephone +49 221 460 208-00
Telefax +49 221 460 208-01
E-Mail info@cevec.com


CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Straße 60-62
51105 Cologne